Mounjaro can be taken indefinitely for weight loss. The FDA classifies obesity as a chronic condition, and the medications approved to treat it, including tirzepatide (the active ingredient in both Mounjaro and its weight-loss counterpart Zepbound), are designed for ongoing use. There is no built-in stopping point, and clinical trial data now confirms that the drug produces sustained weight loss for at least three years of continuous treatment.
Why It’s Considered a Long-Term Medication
Obesity medications work differently than, say, a course of antibiotics. They manage a condition rather than cure it. Tirzepatide works by mimicking two gut hormones that regulate appetite, blood sugar, and how quickly food moves through your digestive system. When you stop taking it, those signals return to their previous state, and the biological drive to regain weight comes back.
The FDA approved Zepbound (tirzepatide for weight loss) specifically for “chronic weight management,” language that signals long-term or lifelong use. Mounjaro itself is approved for type 2 diabetes, but many doctors prescribe it off-label for weight loss using the same active ingredient. In both cases, the expectation is that you continue treatment as long as it’s working and you’re tolerating it well.
What Happens When You Stop
The clearest evidence comes from the SURMOUNT-4 trial, which studied what happens after people discontinue tirzepatide. Participants first took the drug for 36 weeks and lost a significant amount of weight. Then half were switched to a placebo while the other half continued treatment for another year.
The results were stark. Among people who stopped the medication, 82% regained more than a quarter of the weight they had lost within one year. About a third regained 50% to 75% of their lost weight, and roughly one in four gained back 75% or more. Meanwhile, those who stayed on tirzepatide maintained their results. This pattern is consistent across the entire class of GLP-1 medications: the weight loss depends on continued treatment.
How Long Has It Been Studied?
The original approval trials measured outcomes over 72 weeks, roughly a year and a half. That was enough to establish effectiveness but left open questions about what happens further out. A longer-term analysis has since tracked participants for 176 weeks, a full three years, and found that clinically meaningful weight loss was sustained for the entire period.
That three-year mark represents the longest published data available. It doesn’t mean tirzepatide stops working after three years. It simply means that’s how far the formal evidence extends. Many patients and their doctors plan for use well beyond that window, based on the understanding that the drug continues to suppress appetite and regulate metabolism for as long as you take it.
Adjusting Your Dose Over Time
Most people start tirzepatide at a low dose (2.5 mg weekly) and gradually increase over several months to reach a therapeutic level, typically 5 mg, 10 mg, or 15 mg per week. Once you’ve reached your weight loss goal, you don’t necessarily stay at the highest dose.
Some clinicians shift patients to a maintenance dose, which is often lower than the dose used during active weight loss. A maintenance dose of 5 to 7.5 mg weekly is common, and some people stabilize at just 2.5 mg per week, especially when their diet and exercise habits are strong. In certain cases, doctors also experiment with less frequent dosing, such as every other week, to find the minimum amount needed to keep weight stable. This can reduce both side effects and cost over the long term.
Side Effects With Extended Use
The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and occasional vomiting. These tend to be worst during the dose-escalation phase and generally improve once your body adjusts. In clinical trials, gastrointestinal symptoms were mostly mild to moderate and did not lead to a higher rate of serious medical events compared to placebo.
Discontinuation due to side effects did increase at higher doses. In a large meta-analysis, people on tirzepatide were about twice as likely to stop treatment because of side effects compared to those on placebo, though the absolute numbers remained relatively small. Concerns about rarer long-term risks, including pancreatitis and cardiovascular effects, have been flagged but not confirmed. Most clinical trials have followed patients for 72 weeks or less, so the full picture of very long-term safety, beyond three years, is still incomplete.
The Cost Factor
For many people, the practical limit on how long they take Mounjaro isn’t medical but financial. Without insurance coverage for weight loss, the list price can exceed $1,000 per month. Insurance plans that do cover GLP-1 medications for weight management often require periodic documentation that the drug is still producing results, such as proof of continued weight loss or maintenance. Coverage policies vary widely, and some plans impose time limits or require reauthorization every six to twelve months.
If you’re using Mounjaro off-label for weight loss (meaning your prescription is technically for diabetes management), coverage dynamics are different and depend on your specific diagnosis and plan. The financial sustainability of staying on the drug long-term is worth discussing with your prescriber early, before you’ve invested months in a treatment you may not be able to continue.